Custom Search

News

Wednesday 01 February 2006

Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant.

By: Price S, Cumpston A, Altaha R.

Hematology 2006 Feb;11(1):43-4

Immune thrombocytopenia is well recognized post both allogeneic and autologous transplantation. The diagnosis can be difficult as there are generally several complicating features, including delayed marrow recovery and the use of multiple therapies. Treatment can be difficult and conventional approaches are often unsuccessful. We describe a case of presumed immune thrombocytopenia post autologous stem cell transplantation, who appeared to respond to the monoclonal B-cell antibody, rituxmab, which is being increasingly recognized as a therapeutic option in a variety of autoimmune disorders.

Use of this site is subject to the following terms of use